Clinical Trials

Deucrictibant is designed to directly target the ultimate event in the HAE cascade, the interaction of bradykinin with the B2 receptor, a proven mechanism for the treatment of HAE attacks.

Pharvaris aims to bring better oral options to meet the needs of people with HAE for on-demand and prophylactic treatment. We are developing novel, potent and selective B2-receptor antagonist small molecules for the treatment of HAE.

People interested in participating in a clinical trial should speak with their physician.

OUR SCIENCE OUR PIPELINE

rapide-2 logo

RAPIDe-2

Extension study of oral on-demand treatment

  • For whom – people diagnosed with hereditary angioedema (HAE) who participated in RAPIDe-1
  • Purpose – To further assess safety and efficacy of PHVS416 is in relieving symptoms associated with HAE attacks with long-term dosing.
  • Approach – soft capsules taken orally to prevent HAE attacks.

Clinical Trial

rapide-1 logo

RAPIDe-1

Oral on-demand treatment study

  • For whom – people diagnosed with hereditary angioedema (HAE).
  • Purpose – To find out how effective PHVS416 is in relieving symptoms associated with HAE attacks.
  • Approach – soft capsules taken orally to prevent HAE attacks.

For more information, visit the links below:

chapter-1 logoshow active

CHAPTER-1

Oral prophylactic treatment study

  • For whom – people diagnosed with hereditary angioedema (HAE).
  • Purpose – to evaluate PHVS416 in preventing HAE attacks.
  • Approach – soft capsules taken orally to prevent HAE attacks.

For more information, visit the links below:

Learn more about the Expanded Access Policy